Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies

Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies

<p>Abstract</p> <p>Background</p> <p>The United States (US) Food and Drug Administration (FDA) is responsible for the protection of the public health by assuring the safety, effectiveness and security of human drugs and biological products through the enforcement of the...

Full description

Bibliographic Details
Main Authors:	Nguyen Diane, Seoane-Vazquez Enrique, Rodriguez-Monguio Rosa, Montagne Michael
Format:	Article
Language:	English
Published:	BMC 2013-01-01
Series:	BMC Health Services Research
Subjects:	Food and Drug Administration (FDA) Federal drug regulation enforcement Warning letters Notices of violation
Online Access:	http://www.biomedcentral.com/1472-6963/13/27

Similar Items

Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
by: Brent L. Rollins
Published: (2016-04-01)

Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication
by: Bander Balkhi, et al.
Published: (2018-02-01)

Gottlieb, the FDA and dumbing down medicine
by: Robbins RA
Published: (2017-04-01)

Drugs, Devices, and the FDA: Part 1
by: Gail A. Van Norman, MD
Published: (2016-04-01)

The Effect of the FDA VVarning on the Use of Droperidol by U.S. Emergency Physicians
by: Richards, John R, et al.
Published: (2003-01-01)

Review of FDA Public Hearing Transcript on Behind-the-Counter Availability of Certain Drugs
by: Reiss, Matthew, et al.
Published: (2009)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
by: Hao Zhong, et al.
Published: (2018-12-01)

The Conundrum of Online Prescription Drug Promotion Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
by: Isaac Wanasika
Published: (2016-06-01)

Review of FDA Public Hearing Transcript on Behind-the-Counter Availability of Certain Drugs
by: Rasmussen, Ashli, et al.
Published: (2010)

The development of a course of study in FDA drug regulatory procedures
by: Wills, Robin Adele
Published: (1975)

Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies
by: Isidro Palos, et al.
Published: (2017-06-01)

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
by: Chandra P. Leo, et al.
Published: (2020-02-01)

Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization
by: Triana Amen, et al.
Published: (2016-03-01)

FDA efficiency for approval process of COVID-19 therapeutics
by: Christine Cassidy, et al.
Published: (2020-12-01)

Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters
by: Hyosun Kim
Published: (2015-12-01)

Looking Beyond FDA Warning Letters to Explore Unforeseen Trouble Spots in eDTCA: A Response to Recent Commentaries
by: Hyosun Kim
Published: (2016-10-01)

THE IMPACT OF THE NATIONAL CREDIT ACT 34 OF 2005 ON THE ENFORCEMENT OF A MORTGAGE BOND: SEBOLA V STANDARD BANK OF SOUTH AFRICA LTD 2012 5 SA 142 (CC)
by: Michelle MM Fuchs
Published: (2013-08-01)

One and done: Reasons principal investigators conduct only one FDA-regulated drug trial
by: Amy Corneli, PhD, MPH, et al.
Published: (2017-06-01)

The Tip of the Iceberg of Misleading Online Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
by: Barbara Mintzes
Published: (2016-05-01)

Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014–2018) Using RE-AIM
by: Gita A. Toyserkani, et al.
Published: (2020-02-01)

Did E-Cigarette Users Notice the New European Union’s E-Cigarette Legislation? Findings from the 2015–2017 International Tobacco Control (ITC) Netherlands Survey
by: Dirk-Jan A. van Mourik, et al.
Published: (2019-08-01)

A Drug Combination Screen Identifies Drugs Active against Amoxicillin-induced Round Bodies of Borrelia burgdorferi Persisters from an FDA Drug Library
by: Jie eFeng, et al.
Published: (2016-05-01)

The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?
by: Michele Fornaro, et al.
Published: (2019-05-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2021-12-01)

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
by: Daniel A. Rodrigues, et al.
Published: (2019-05-01)

Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library
by: Jie Feng, et al.
Published: (2015-09-01)

Virtual Screening of FDA-Approved Drugs against Triose Phosphate Isomerase from <em>Entamoeba histolytica</em> and <em>Giardia lamblia </em>Identifies Inhibitors of Their Trophozoite Growth Phase
by: Alfredo Juárez-Saldivar, et al.
Published: (2021-05-01)

Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice
by: Chunfeng Li, et al.
Published: (2017-10-01)

Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014–2018)
by: Linda Huynh, et al.
Published: (2021-08-01)

Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of <i>Plasmodium vivax</i> Malaria and Prophylaxis of Malaria
by: Annie Mayence, et al.
Published: (2019-07-01)

Legal Enforcement Efforts On Traffic Violations Made By Students Under The Age In Surabaya City
by: Ebit Rudianto, et al.
Published: (2021-03-01)

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
by: Annie Mayence, et al.
Published: (2019-03-01)

Comparison of Findings from Published Weight Loss Trials for Orlistat to the Findings Used by the Food and Drug Administration (FDA)
by: Balmaceda, Zaira, et al.
Published: (2010)

Information Extraction From FDA Drug Labeling to Enhance Product-Specific Guidance Assessment Using Natural Language Processing
by: Yiwen Shi, et al.
Published: (2021-06-01)

FDA commissioner Gottlieb resigns
by: Robbins RA
Published: (2019-03-01)

Information to Improve Public Perceptions of the Food and Drug Administration (FDA’s) Tobacco Regulatory Role
by: Amira Osman, et al.
Published: (2018-04-01)

Screening of an FDA-Approved Library for Novel Drugs against <i>Y. pestis</i>
by: David Gur, et al.
Published: (2021-01-01)

In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors
by: Arun Bahadur Gurung, et al.
Published: (2020-10-01)

Enforcement of Criminal Law in Statement Illegal Medicine Circulation
by: Hardiono Adisaputra, et al.
Published: (2019-11-01)

Acrylamide in Food – EU versus FDA Approaches
by: Gabriel Mustăţea, et al.
Published: (2015-11-01)

Cannot write session to /tmp/vufind_sessions/sess_jafh0rcn58kl13hcugp93uihor